welcome to the website of the
17th St.Gallen International Breast Cancer Conference 2021
17 – 21 March 2021, online worldwide
The scientific chairs and the organizers invited you to our first ever virtual 17th St.Gallen International Breast Cancer Conference from 17 to 21 March 2021! Experts of all major cooperative groups and centres worldwide actively engaged in basic and clinical research as well as in clinical management of patients with breast cancer presented their latest data, critically reviewed by leading specialists in the field, culminated in the famous St.Gallen International Breast Cancer Consensus Session.
We want to take this opportunity to thank you for your contribution to the 17th St.Gallen International Breast Cancer Conference. It is our great pleasure to see so many delegates come together every two years to learn about the newest developments in treatment of women with early breast cancer and take part in the unique St.Gallen International Breast Cancer Consensus Session.
Thank you for being with us and a special thank to our faculty members, panelists and sponsors for their valuable contribution to this conference!
Highlight of the conference
In case you missed the conference, take the opportunity to find out more about the conference and it’s highlight, the St.Gallen International Consensus Session, in the interview of Congress Report with our St.Gallen Oncology Conferences board member, Prof. Walter Weber. Find out more here.
Save the date
The next St.Gallen International Breast Cancer Conference will take place from 15 – 18 March 2023. We look forward to welcoming you again in 2023!
St.Gallen Consensus
The virtual 17th St.Gallen International Breast Cancer Conference closed as usual with an update of the widely acknowledged St.Gallen International Breast Cancer Consensus on the optimal treatment of women with early breast cancer for the following two years. The consensus and its related scientific core issues are now online as a special article in the Annals of Oncology. You can find the manuscript here:
Webcasts
The webcasts of the scientific programme will be available here for conference participants for six months starting from Monday, 22 March 2021. This service is supported by an educational grant provided by Veracyte. Please note, that the consensus session is not included in the webcasts.
Thank you for your contribution. Looking forward to welcoming you again in 2023!
Your SG-BCC 2021 Organising Team
St.Gallen Oncology Conferences
c/o Tumor- and Breast Center ZeTuP
Rorschacherstrasse 150, 9006 St.Gallen/Switzerland
sgbcc@oncoconferences.ch
www.sg-bcc.org
chairs
Meet our chairs:
Conference founder and honorary chair
Prof. Dr. med. Hans-Joerg Senn, c/o Tumor and Breast Center ZeTuP St.Gallen / Switzerland
Conference co-chairs
Univ. Prof. Dr. Michael Gnant, Medical University of Vienna / Austria
Prof. Dr. med. Beat Thürlimann, Breast Centre, Kantonsspital St.Gallen / Switzerland
Scientific Programme-Chairpersons
Harold Burstein, Boston/MA, USA
Giuseppe Curigliano, Milano/Italy
Michael Gnant, Vienna/Austria
Meredith Regan, Boston/MA, USA
Hans-Jörg Senn, St.Gallen/Switzerland
Beat Thürlimann, St.Gallen/Switzerland
Walter Weber, Basel/Switzerland
Eric Winer, Boston/MA, USA
faculty members
Conflict of Interest Statements
All faculty members of the scientific programme have submitted a conflict-of-interest-statement.
The summary of all statements is available here
.
| Aapro Matti, Genolier Cancer Centre, Genolier, Switzerland |
| Aebi Stefan, Tumorzentrum LUKS, Luzerner Kantonsspital, Lucerne, Switzerland |
| André Fabrice, Institut de Cancérologie Gustave Roussy, Villejuif, France |
| Barrios Carlos, Centro de Pesquisa em Oncologia, Hospital São Lucas, PUCRS, Porto Alegre, Brazil |
| Bergh Jonas, Karolinska Institutet and University Hospital, Stockholm, Sweden |
| Bonnefoi Herve, University of Bordeaux 2, Bordeaux, France |
| Bretel Morales Denisse, Oncosalud, Lima, Peru |
| Brucker Sara, Universitäts-Frauenklinik Tübingen, Tübingen, Germany |
| Burstein Harold, Dana-Farber Cancer Institute, Boston, United States |
| Cameron David, The University of Edinburgh, Edinburgh, United Kingdom |
| Cardoso Fatima, Champalimaud Cancer Center, Lisbon, Portugal |
| Carey Lisa, UNC – Lineberger Comprehensive Cancer Center, Chapel Hill, United States |
| Cescon Dave, Princess Margaret Hospital, Toronto, Canada |
| Chua Boon, Prince of Wales Hospital, Randwick, Australia |
| Ciruelos Eva, University Hospital 12 de Octubre, Madrid, Spain |
| Coates Alan, University of Sydney, Australia |
| Colleoni Marco, European Institute of Oncology, Milano, Italy |
| Cortes Javier, International Breast Cancer Center, Barcelona, Spain |
| Curigliano Giuseppe, European Institute of Oncology, Milano, Italy |
| Delaloge Suzette, Institut de Cancérologie Gustave Roussy, Villejuif, France |
| Denkert Carsten, Institut für Pathologie, Charité – Universitätsmedizin Berlin, Berlin, Germany |
| Dubsky Peter, Brustzentrum Hirslanden Klinik St. Anna, Lucerne, Switzerland |
| Ejlertsen Bent, DBCG Secretariat and Dept. of Oncology, Rigshospitalet, Copenhagen, Denmark |
| Fitzal Florian, Medical University Vienna, Vienna, Austria |
| Francis Prudence, Peter McCallum Cancer Centre, Melbourne, Australia |
| Galimberti Viviana, European Institute of Oncology, Milano, Italy |
| Gamal Heba, National Cancer Institute, Cairo, Egypt |
| Garber Judy, Dana-Farber Cancer Institute, Boston, United States |
| Giordano Sharon, The University of Texas MD Anderson Cancer Center, Houston, United States |
| Gnant Michael, Medical University Vienna, Vienna, Austria |
| Gradishar William, Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, United States |
| Gulluoglu Bahadir, Marmara University School Of Medicine, Istanbul, Turkey |
| Harbeck Nadia, Frauenkliniken Maistrasse-Innenstadt und Großhadern, Munich, Germany |
| Heil Jörg, Heidelberg University, Heidelberg, Germany |
| Huang Chiun-Sheng, National Taiwan University Hospital, Taipei, Taiwan |
| Huober Jens, Kantonsspital St.Gallen, St.Gallen, Switzerland |
| Ilbawi Andre, WHO Cancer Control Program, Switzerland |
| Jiang Zefei, 307 Hospital No.8, Beijing, China |
| Johnston Steven, Royal Marsden Hospital, London, United Kingdom |
| King Tari, Dana-Farber Cancer Institute, Boston, United States |
| Krop Ian, Dana-Farber Cancer Institute, Boston, United States |
| Lee Eun Sook, National Cancer Center, Goyang-si, Korea |
| Lin Nancy, Dana-Farber Cancer Institute, Boston, United States |
| Loi Sherene, Peter McCallum Cancer Centre, Melbourne, Australia |
| Loibl Sibylle, GBG Forschungs GmbH, Neu-Isenburg, Germany |
| Morrow Monica, Memorial Sloan-Kettering Cancer Center, New York, United States |
| Pagani Olivia, Institute of Oncology Southern Switzerland, Bellinzona, Switzerland |
| Partridge Ann, Dana-Farber Cancer Institute, Boston, United States |
| Piccart Martine, Institut Jules Bordet, Brussels, Belgium |
| Poortmans Philip, Iridium Kankernetwerk & University of Antwerp, Antwerp, Belgium |
| Prat Aleix, Hospital Clinic of Barcelona, Barcelona, Spain |
| Pusic Andrea, Brigham and Women’s Hospital, Boston, United States |
| Regan Meredith, Dana-Farber Cancer Institute, Boston, United States |
| Rubio Isabella, Clinica Universidad de Navarra, Madrid, Spain |
| Rugo Hope, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, United States |
| Rutgers Emiel, Netherlands Cancer Institute, Amsterdam, Netherlands |
| Sedlmayer Felix, Paracelsus Medical University, Salzburg, Austria |
| Semiglazov Vladimir, N.N.Petrov Research Institute of Oncology, St. Petersburg, Russian Federation |
| Shao Zhiming, Fudan University Cancer Hospital, Shanghai, China |
| Spanic Tanja, Europa Donna, Ljubljana, Slovenia |
| Tesarova Petra, Charles University Hospital and 1st medical faculty, Prague, Czech Republic |
| Thürlimann Beat, Kantonsspital St.Gallen, St.Gallen, Switzerland |
| Tjulandin Sergei, N.N. Blokhin Cancer Research Center, Moscow, Russian Federation |
| Toi Masakazu, Graduate School of Medicine Kyoto University, Kyoto City, Japan |
| Trudeau Maureen, University of Toronto, Toronto, Canada |
| Turner Nicholas, The Royal Marsden Hospital, London, United Kingdom |
| Tutt Andrew, Breast Cancer Now Research Centre, London, United Kingdom |
| Vaz Luis Ines, Institut de Cancérologie Gustave Roussy, Villejuif, France |
| Viale Giuseppe, Istituto Europeo di Oncologia, Milano, Italy |
| Watanabe Toru, Hamamatsu Oncology Center, Hamamatsu, Japan |
| Weber Walter, Klinik für Allgemeinchirurgie, Universitätsspital Basel, Basel, Switzerland |
| Winer Eric P., Dana-Farber Cancer Institute, Boston, United States |
| Xu Binghe, National Cancer Center, Beijing, China |
subject to changes
conference programme
Accelerating access to innovation in early breast cancer
Browse through our scientific programme, read the awardees‘ contribution and find out more about the industry symposia, our virtual conference platform and all conference-related matters.
Download the final programme here
Thank you to all participants for being with us and a special thank to our faculty members and panelists for their valuable contribution to this conference!
the St.Gallen Consensus on the optimal Treatment of women with early breast cancer
The St.Gallen International Breast Cancer Conference 2021 closed as usual with an update of the widely acknowledged St.Gallen International Breast Cancer Consensus on the optimal Treatment of Women with early breast cancer.
In order to allow even more room for discussions on early breast cancer care, the 2021 Consensus Session took place on two days, 20 and 21 March 2021. For the first time ever, the consensus panel decided that they want to hear the questions of the audience directly, who made good use of the new Q&A Tool.
The list of all members of the St.Gallen 2021 International Breast Cancer Consensus panel can be found here.
Publication 2021
The consensus and its related scientific core issues are now available online in a special article of the Annals of Oncology:
Publications 2019:
Estimating the benefits of therapy for early-stage breast cancer: read the St.Gallen International Consensus Guidelines for the Primary therapy of early breast cancer 2019 here.
webcasts
The webcasts of the pre-recorded on-demand sessions and the live discussion sessions from 17 to 19 March 2021 can be accessed with the link below. Please note, that the consensus session is not included in the webcasts.
The webcasts are exclusively supported by 
Click on the links below to view the webcasts of the St.Gallen International Breast Cancer Conferences of the previous years:
certificate
CME Points & Certificate of Attendance
The Certificate of Attendance including the CME credits will be sent to all participants by e-mail upon completion of the online survey. The link to the online survey will be provided by e-mail.
Full conference participation counts for 10 CME credit points (17 – 21 March 2021) – credits will be assigned per day of participation. Please find the breakdown of ECMEC®s per day below:
17.03.2021 – 2.00 CME credit points
18.03.2021 – 2.00 CME credit points
19.03.2021 – 2.00 CME credit points
20.03.2021 – 2.00 CME credit points
21.03.2021 – 2.00 CME credit points
award winners
St.Gallen International Breast Cancer Award Winner 2021
The Foundation Council of “St.Gallen Oncology Conferences“ (SONK) proudly announces the recipient of the “St.Gallen International Breast Cancer Award 2021“, which was delivered during the 17th St.Gallen International Breast Cancer Conference, 17-21 March, 2021 to:
Prof. Philip Poortmans
Iridium Netwerk & University of Antwerp, Belgium
> find out more about Prof. Philip Poortmans
ESO Umberto Veronesi Memorial Award Winner 2021
Fatima Cardoso, MD
Director, Breast Unit, Champalimaud Clinical Center, Lisbon, Portugal
President, ABC Global Alliance
abstracts
accepted abstracts
We are pleased to publish herewith the list of all accepted abstracts:
book of abstracts
All abstracts have been published in an electronic supplement issue to the journal “The Breast” by Elsevier Publishers. The abstracts are Open Access on both the journal website and on ScienceDirect.
best poster awards 2021
We proudly present the three winners of the St.Gallen Oncology Conferences Best Poster Awards 2021:
We thank our partners and sponsors who support the 17th St.Gallen International Breast Cancer Conference.
co-operating partner
sponsoring partner
exhibitors
promotional partner
satellite symposia programme
| Wednesday, 17 March 2021 | |
| 10.30 – 12.00 (CET) | Answer in CME (Lilly) |
| 12.15 – 13.45 (CET) | F. Hoffmann-La Roche |
| 16.45 – 18.15 (CET) | Pfizer Oncology |
| Thursday, 18 March 2021 | |
| 12.45 – 13.45 (CET) | Seagen |
| 16.45 – 18.45 (CET) | Daiichi Sankyo Europe GmbH |
| 18.30 – 19.30 (CET) | NOVARTIS |
| Friday, 19 March 2021 | |
| 12.45 – 13.45 (CET) | Exact Sciences |
| 16.45 – 18.15 (CET) | PIERRE FABRE |
Wednesday, 17 March 2021
10.30 – 12.00 (CET)
When Recurrence is in the Cards: Recognizing and Addressing Risk in Patients with HR-positive, HER2-negative Early Breast Cancer
Faculty:
William J. Gradishar, USA
Nadia Harbeck, Germany
- Welcome and Introductions
- Identifying Which Way the Deck is Stacked for Patients with Early Breast Cancer
- Showing Your Cards When it Comes to Risk Assessment for Early Breast Cancer
- Addressing the Cards Dealt with Evolving Treatment for Early Breast Cancer
- Using the Cards Up Your Sleeve to Optimize Treatment for Early Breast Cancer
- Q&A
- Take Home Learnings
12.15 – 13.45 (CET)
Advancing care for patients with early breast cancer
- 12:15–12:20 Welcome and introduction
Dr Giampaolo Bianchini, Italy - 12:20–12:40 Making optimal treatment decisions for patients with HER2-positive eBC
Dr Giampaolo Bianchini, Italy - 12:40–12:50 Improving treatment beyond efficacy for patients with HER2-positive eBC
Prof. Christian Jackisch, Germany - 12:50–13:10 The role of cancer immunotherapy in the treatment of patients with early triple negative breast cancer
Prof. Peter Schmid, UK - 13:10–13:20 Beyond efficacy: Patient-reported outcomes from cancer immunotherapy trials in early triple negative breast cancer
Dr Elizabeth Mittendorf, USA - 13:20–13:35 Panel discussion
Moderated by Dr Giampaolo Bianchini, Italy - 13:35–13:40 Dr Giampaolo Bianchini
16.45 – 18.15 (CET)
The value of experience: Improving patient outcomes in a new era of clinical evidence
- Defining the moment: Treatment discussions in HR+/HER2- breast cancer
Giuseppe Curigliano, Italy - The era of genetic testing: Treatment selection for patients with germline BRCA-mutated locally advanced or metastatic breast cancer
Paul Cottu, France - Q&A
Giuseppe Curigliano, Italy
Paul Cottu, France - The time is now: Harnessing the value of real-world evidence in clinical decision making
Winson Cheung, Canada
Paul Cottu, France - Q&A
Winson Cheung, Canada
Paul Cottu, France - Looking forward: Future directions of treatment in HR+/HER2- metastatic breast cancer
Giuseppe Curigliano, Italy
Thursday, 18 March 2021
12.45 – 13.45 (CET)
Experts exploring HER2CLIMB
Faculty:
Dr Stephanie Sutherland, UK (Chair)
Prof. Sibylle Loibl, Germany
Dr Mafalda Oliveira, Spain
- Understanding the HER2CLIMB study design
- Exploring the data: HER2CLIMB efficacy and safety
- Diving Deeper: HER2CLIMB subgroups
- Live Q&A session
- Short closing statement
16.45 – 18.15 (CET)
Next-generation antibody-drug conjugates: New hope for HER2
- Opening remarks
Jean-Yves Pierga, France (Co-Chair) - The innovative mode of action of next-generation antibody-drug conjugates (ADCs)
Matthias Peipp, Germany - Next-generation ADCs in the treatment of advanced breast cancer (ABC)
Rupert Bartsch, Austria - New hope for HER2: Early intervention in HER2-positive breast cancer
Sibylle Loibl, Germany - New recommendations for HER2: Guideline update
Fatima Cardoso, Portugal - New paradigm for HER2: Place of the next-generation ADCs in the treatment landscape
Panel Discussion and Q&A
All speakers - Closing remarks
Nadia Harbeck, Germany (Co-Chair)
18.30 – 19.30 (CET)
Reimagining Treatment of HR+, HER2– EBC
Speakers:
Aleix Prat, Spain
Giuseppe Curigliano, Italy
- Opening remarks
- Recurrence Risk: A Clinical or Genomic Assessment?
- Who May Benefit from CDK4/6i in the EBC Setting?
- What Might the Future Look Like in EBC?
- Live Q&A session
- Closing remarks
Friday, 19 March 2021
12.45 – 13.45 (CET)
Confidence in treatment decisions for HR+, HER2- early breast cancer patients
Chair:
Mark Harries, UK
- Recent landmark RxPONDER results: impact on treatment decisions for node-positive patients
Suzette Delaloge, France - An integrated view of the latest clinical evidence
Giuseppe Curigliano, Italy - What will we do on Monday morning?
Moderated by Mark Harries with the entire panel - Patient cases and discussion
16.45 – 18.15 (CET)
EXTEND HER PROTECTION AGAINST BREAST CANCER RECURRENCES
Patient cases in HER2+ early breast cancer
- Welcome and introduction
Prof. S. Loibl (Chair), Germany - Practice update | Evolving concepts in HER2+/HR+ early breast cancer
Prof. S. Loibl - Managing risk | A patient with node-positive HER2+/HR+ breast cancer after adjuvant treatment
Prof. R. Bartsch, Austria - Check the narrative | Preventing recurrence in a patient after neoadjuvant therapy
Dr. J. O’Shaughnessy, USA - HER experience | Understanding the patient’s perspective
Panel discussion
All faculty joined by Ms Laure Guéroult-Accolas, Patients en réseau - Live Q&A and close
Prof. S. Loibl
impressions
Thank you for sharing so many photos of your virtual participation at the 17th St.Gallen International Breast Cancer Conference 2021! Have a look at the many vivid photos and the colorful impressions we have captured for you:
You can’t find your photo? Send it to sgbcc@oncoconferences.ch and we will post it.
contact
Scientific programme and faculty
St. Gallen Oncology Conferences (SONK)
c/o Tumor and Breast Center ZeTuP
Rorschacherstrasse 150
9006 St.Gallen / Switzerland
+41 71 243 00 32
info@oncoconferences.ch
Industrial exhibition, satellite symposia, registration, hotel accommodation, networking programme, abstract submission
Mondial Congress & Events
Mondial GmbH & Co. KG
Operngasse 20b, 1040 Vienna / Austria
+43 1 588 04 0
bcc21@mondial-congress.com